
bioMérieux Investor Relations Material
Latest events

Q1 2025
bioMérieux
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from bioMérieux S.A
Access all reports
bioMérieux S.A. is a global biotechnology company that specializes in the development, manufacturing, and marketing of in vitro diagnostic solutions for medical and industrial applications. The company’s products include diagnostic tools for infectious diseases, oncology, cardiovascular diseases, and food safety testing. bioMérieux offers a range of systems, reagents, and software designed for microbiology, immunoassays, and molecular biology, helping healthcare providers and laboratories detect pathogens and analyze biological samples. The company also serves industrial markets, providing solutions for food safety, pharmaceutical quality control, and environmental monitoring. The company is headquartered in Marcy-l'Étoile, France, and its shares are listed on Euronext Paris.
Key slides for bioMérieux S.A


Q4 2024
bioMérieux S.A


H1 2024
bioMérieux S.A
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
BIM
Country
🇫🇷 France